Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Julien Taı̈eb

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9955-4753; OpenAlex author ID A5024180743. Sources: OpenAlex.

Their work

Papers
47 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
169
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 4 papers · 2015: 4 papers · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 5 papers · 2021: 3 papers · 2022: 6 papers · 2023: 6 papers · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 47

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… Co-author DOI 10.1016/j.eclinm.2026.103998↗
  3. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  4. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  5. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  6. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
  7. Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.esmoop.2024.103975↗
  8. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  9. Nutrition support in pancreatic cancer: An expert statement on practical implementation of French guidelines. Co-author DOI 10.1016/j.clinre.2023.102153↗
  10. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  11. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world stud… Co-author DOI 10.1186/s12885-023-11377-1↗
  12. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  13. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  14. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  15. BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2022.101880↗
  16. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Co-author DOI 10.1038/s41416-021-01624-2↗
  17. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
  18. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
  19. Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac055↗
  20. Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database. Co-author DOI 10.3390/cancers14051105↗
  21. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Last author DOI 10.1038/s41416-021-01341-w↗
  22. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Co-author DOI 10.2217/fon-2020-0749↗
  23. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Co-author DOI 10.3390/cancers13112797↗
  24. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter … Last author DOI 10.1016/j.clinre.2019.08.009↗
  25. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Last author DOI 10.1016/j.ctrv.2020.102028↗
  26. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/j.ejca.2020.05.018↗
  27. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observa… Co-author DOI 10.1136/esmoopen-2019-000587↗
  28. How I treat pancreatic cancer. Co-author DOI 10.1136/esmoopen-2020-000818↗
  29. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leu… Co-author DOI 10.1002/cam4.2311↗
  30. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarci… Last author DOI 10.1016/j.clinre.2019.03.007↗
  31. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Last author DOI 10.1177/1756284819878660↗
  32. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  33. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  34. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR)… Co-author DOI 10.1016/s2468-1253(17)30046-8↗
  35. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. Co-author DOI 10.1007/s11136-015-1198-x↗
  36. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  37. Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre coh… Last author DOI 10.1038/bjc.2016.70↗
  38. Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a mu… Co-author DOI 10.1186/s12885-016-2860-6↗
  39. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Last author DOI 10.1038/bjc.2015.328↗
  40. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Last author DOI 10.1245/s10434-014-3898-9↗
  41. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  42. Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A… Co-author DOI 10.1371/journal.pone.0125350↗
  43. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Last author DOI 10.1016/j.clinre.2014.01.005↗
  44. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  45. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastat… Last author DOI 10.1016/j.ejca.2014.09.015↗
  46. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. Last author DOI 10.1186/1471-2407-14-441↗
  47. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Last author DOI 10.1016/j.clinre.2011.02.002↗

Closest collaborators

The 25 strongest of 169 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 18 shared papers, 2011–2026 · strength 1.83
  2. Raëf Abdallah · 8 shared papers, 2020–2026 · strength 1.30
  3. David Tougeron · 9 shared papers, 2015–2026 · strength 1.11
  4. Isabelle Trouilloud · 12 shared papers, 2011–2026 · strength 1.03
  5. Simon Pernot · 9 shared papers, 2014–2026 · strength 0.98
  6. Laëtitia Dahan · 7 shared papers, 2014–2026 · strength 0.81
  7. Jean–Marc Phelip · 5 shared papers, 2019–2026 · strength 0.72
  8. Nicolas Williet · 6 shared papers, 2018–2025 · strength 0.61
  9. Pierre Laurent‐Puig · 4 shared papers, 2020–2026 · strength 0.61
  10. Dominique Béchade · 5 shared papers, 2019–2025 · strength 0.59
  11. Aziz Zaanan · 8 shared papers, 2011–2024 · strength 0.58
  12. Édouard Auclin · 5 shared papers, 2019–2023 · strength 0.58
  13. Gerald W. Prager · 4 shared papers, 2020–2023 · strength 0.57
  14. Franck Bonnetain · 9 shared papers, 2014–2025 · strength 0.53
  15. Lysiane Marthey · 7 shared papers, 2015–2025 · strength 0.49
  16. Shulin Zhao · 3 shared papers, 2020–2026 · strength 0.48
  17. Louis de Mestier · 3 shared papers, 2018–2026 · strength 0.46
  18. Olivier Bouché · 3 shared papers, 2018–2026 · strength 0.46
  19. Teresa Mercade Macarulla · 4 shared papers, 2014–2023 · strength 0.46
  20. Romain Coriat · 6 shared papers, 2015–2025 · strength 0.45
  21. Daniel Pietrasz · 5 shared papers, 2015–2022 · strength 0.43
  22. Anne‐Laure Pointet · 5 shared papers, 2016–2025 · strength 0.42
  23. Pascal R. Hammel · 6 shared papers, 2014–2025 · strength 0.42
  24. Christoph Benedikt Westphalen · 3 shared papers, 2020–2023 · strength 0.40
  25. António Sá Cunha · 6 shared papers, 2015–2021 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.